Fig. 6.

AMPK phosphorylation/activation leads to inhibition of SREBP-1 activation. (A) AMPK activation decreases SREBP activity in AML12 cells. Both AML12 cells and HEP3B cells were infected with control null virus (Ad-null, 50 multiplicities of infection), or an adenovirus expressing the constitutively active form of AMPK (Ad-AMPK-CA) for 24 h. The phosphorylation of AMPK and ACC were analyzed by immunoblotting. (B) Inhibition of AMPK activation can reverse the decrease of SREBP activity caused by AMPK activation. AML12 cells were treated with or without compound C (20 µM), as well as with constitutively activated (Ad-AMPK-CA) or dominant negative (Ad-AMPK-DN) forms of AMPK for 24 h. (C) AMPK activation leading to decreased level of triglyceride. The treatment was the same as in (B), but for 48 h, and triglycerides were measured using commercial kit. ^**p < 0.01.